DelveInsight’s ‘Glioblastoma Pipeline Insight 2022‘ report provides comprehensive global coverage of available, marketed, and pipeline glioblastoma therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the glioblastoma pipeline domain.
For glioblastoma emerging drugs, the glioblastoma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Some of the Key Highlights from Glioblastoma Pipeline Report
- Over 100+ glioblastoma pipeline therapies are in various stages of growth, and their anticipated acceptance in the glioblastoma market would significantly increase market revenue.
- Leading glioblastoma companies such as Array Biopharma, AstraZeneca, Doule bond Pharmaceuticals, Philogen, Immatics N.V, BioNTech, InovioPharma, Noxxon Pharma, Celgene Corporation, Karyo Pharma, Neugate Theranostics, Novartis, Orphelia Pharma, Merck, Acerta Pharma, Genenta Science, CNS Pharmaceutical, Pfizer, Roche, Oncotelic Therapeutics, Autotelic Therapeutics, ACADIA Pharmaceuticals, Mayo Clinic, Cytogel, Xgene Pharmaceutical, Ascletis, 3-V Biosciences, Yumanity Therapeutics, and others are evaluating novel glioblastoma treatment drugs candidate to improve the treatment landscape.
- Key glioblastoma pipeline therapies in various stages of development include Onfekafuspalfa, PLX3397, APVAC1, INO5401, Olaptesed pegol, Selinexor, L19TNF, H1PV, NG101m, ACP196, Temferon, Berubicin Hydrochloride, VXM01, Avelumab, Trabedersen, TVB2640, AZD1390, YTX7739, WP1122, and others.
- Out of the emerging glioblastoma therapies, Trabedersen is in Phase III of clinical development, whereas, Selinexor is in Phase II stage of trials.
- Glioblastoma pipeline therapies in the early stage of development include AZD1390 in Phase I of clinical trials.
Request a sample and discover the recent advances in glioblastoma treatment @ Glioblastoma Pipeline Insight and Outlook
Glioblastoma is a deadly form of cancer that can develop in the brain or spinal cord. Glioblastoma develops from astrocytes, which are cells that nourish nerve cells. It can develop at any age, but it is more common in elderly persons. It can aggravate headaches, nausea, vomiting, and seizures. The glioblastoma causes are unknown.
Glioblastoma symptoms vary according to tumor type, as well as tumor size, location, and rate of growth. Glioblastoma symptoms include headache, nausea or vomiting, confusion or deterioration in brain function, memory loss, personality changes or irritability, and difficulties balancing. Computed tomography (CT or CAT scan) and magnetic resonance imaging (MRI) are two diagnostic instruments (MRI) widely used for glioblastoma diagnosis. Glioblastoma treatments may slow the progression of cancer and reduce signs and symptoms.
For more information about the disease, causes, and treatment, visit: Glioblastoma Pipeline Landscape
Glioblastoma Pipeline Analysis: Drug Profile
TVB2640 is an oral, selective fatty acid synthase (FASN) inhibitor. By inhibiting novo lipogenesis, TVB2640 reduces energy supply and disrupts membrane phospholipid composition in tumor cells (DNL). FASN is a critical enzyme that regulates DNL. It is currently in Phase III development for the glioblastoma treatment.
Trabedersen: Oncotelic Therapeutics
Trabedersen is an antisense TGF-2 inhibitor used to treat solid tumors, particularly brain cancer in adults and DIPG in children. Trabedersen (OT101) is a new antisense oligodeoxynucleotide (ODN) developed by Oncotelic for the treatment of patients with pancreatic carcinoma, malignant melanoma, colorectal carcinoma, high-grade glioma (HGG), and other TGF-2 overexpressing cancers (e.g., prostate carcinoma, renal cell carcinoma, etc.). TGF- is overexpressed in malignancies, suppressing the host’s innate immune response to the tumors. OT-101 treatment removes the TGF-cloaking effect, allowing innate or therapeutic immunity to target and eradicate tumors. Currently, the drug is in Phase III development for glioblastoma treatment.
Gain more knowledge on emerging glioblastoma drugs @ Glioblastoma Treatment Drugs
Glioblastoma Pipeline Therapies and Key Companies
- TVB2640:Ascletis Pharma
- Trabedersen: Oncotelic Therapeutics
- Selinexor: Karyopharm Therapeutics
- Onfekafuspalfa: Philogen
- AZD1390: AstraZeneca
- YTX7739: Yumanity Therapeutics
Learn more about the glioblastoma FDA-approved drugs @ Glioblastoma Clinical Trials
- By Product Type
- Combination Therapy
- By Stage
- Phase I
- Phase II
- Phase III
- By Route of Administration
- By Molecule Type
- Monoclonal Antibody
- Small Molecule
- Gene Therapy
Scope of the Glioblastoma Report
Key Glioblastoma Companies: Array Biopharma (NYSE: ARRY), AstraZeneca (NASDAQ: AZN), Doule bond Pharmaceuticals, Philogen (BIT: PHIL), Immatics N.V (NASDAQ: IMTX), BioNTech (NASDAQ: BNTX), InovioPharma, Noxxon Pharma (EPA: ALNOX), Celgene Corporation, Karyo Pharma (NASDAQ: KPTI), Neugate Theranostics, Novartis (NYSE: NVS), Orphelia Pharma, Merck (NYSE: MRK), Acerta Pharma, Genenta Science (NASDAQ: GNTA), CNS Pharmaceutical (NASDAQ: CNSP), Pfizer (NYSE: PFE), Roche (SWX:ROG), Oncotelic Therapeutics (OTCMKTS: OTLC), Autotelic Therapeutics, ACADIA Pharmaceuticals (NASDAQ: ACAD), Mayo Clinic, Cytogel, Xgene Pharmaceutical, Ascletis (OTCMKTS: ASCLF), 3-V Biosciences, Yumanity Therapeutics (NASDAQ: YMTX), and others
Key Glioblastoma Pipeline Therapies: Onfekafuspalfa, PLX3397, APVAC1, INO5401, Olaptesed pegol, Selinexor, L19TNF, H1PV, NG101m, ACP196, Temferon, Berubicin Hydrochloride, VXM01, Avelumab, Trabedersen, TVB2640, AZD1390, YTX7739, WP1122, and others
Table of Contents
|1.||Glioblastoma Pipeline Report Introduction|
|2.||Glioblastoma Pipeline Report Executive Summary|
|3.||Glioblastoma Pipeline: Overview|
|4.||Analytical Perspective In-depth Commercial Assessment|
|5.||Glioblastoma Pipeline Therapeutics|
|6.||Glioblastoma Pipeline: Late Stage Products (Pre-registration)|
|7.||Glioblastoma Pipeline: Late Stage Products (Phase III)|
|8.||Glioblastoma Pipeline: Mid Stage Products (Phase II)|
|9.||Glioblastoma Pipeline: Early Stage Products (Phase I)|
|10.||Glioblastoma Pipeline Therapeutic Assessment|
|11.||Inactive Products in the Glioblastoma Pipeline|
|12.||Company-University Collaborations (Licensing/Partnering) Analysis|
|14.||Key Products in the Glioblastoma Pipeline|
|16.||Market Drivers and Barriers|
|17.||Future Perspectives and Conclusion|
Got queries? Reach out for more information @ Glioblastoma Drug Pipeline Assessment
Glioblastoma Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key glioblastoma companies including Orphelia Pharma, Merck, Acerta Pharma, Genenta Science, CNS Pharmaceutical, Pfizer, Roche, among others.
Glioblastoma Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical and forecasted glioblastoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Recurrent Glioblastoma Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key recurrent glioblastoma companies including Genenta Science, CNS Pharmaceutical, Pfizer, Roche, among others.
Glioblastoma Multiforme Market Insights, Epidemiology, and Market Forecast-2030 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key glioblastoma multiforme companies including CNS Pharmaceutical, Pfizer, Roche, Autotelic Therapeutics, among others.
Glioblastoma Multiforme Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key glioblastoma multiforme companies, including CNS Pharmaceutical, Pfizer, Roche, Autotelic Therapeutics, among others.
Recurrent Glioblastoma Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical, and forecasted recurrent glioblastoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Other Trending Reports
Cell And Gene Therapy For Multiple Myeloma Market | Fallopian Tube Cancer Market | Atherectomy Devices Market | Oncolytic Virus Cancer Therapy Market | Urinary Incontinence Market | Cholangiocarcinoma Market | Tissue Heart Valves/Cardiovascular Prosthetic Devices Market | Artificial Disc Market | Obesity Market | Cerebral Infarction Market | Hematuria Market | Diabetes Market | Spinal Fusion Devices Market | Panuveitis Market | Prosthetic Heart Valve Market
Latest Healthcare Blogs
- Genital Warts Treatment Market
- Vaccines Market Outlook
- Top Cardiac Devices For Heart Disease Prevention
- Burn Treatment Landscape
- Chlamydia Treatment
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.